Stock EXTX EXACT THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Financials EXACT Therapeutics

Equities

EXTX

NO0010852213

Biotechnology & Medical Research

Real-time Oslo Bors
Other stock markets
 08:15:00 06/05/2024 pm IST 		5-day change 1st Jan Change
6.15 NOK -8.89% Intraday chart for EXACT Therapeutics -9.56% -48.75%
19/04 EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study MT

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 884 521.9 360 385
Enterprise Value (EV) 1 724.4 419.9 292.3 339.7
P/E ratio -26.7 x -8.9 x -8.96 x -7.95 x
Yield - - - -
Capitalization / Revenue - 10,036 x 792 x 86,354 x
EV / Revenue - 8,075 x 643 x 76,207 x
EV / EBITDA -21.3 x -7.28 x -7.44 x -7.27 x
EV / FCF -4,57,04,416 x -1,21,24,588 x -1,51,14,711 x -1,15,76,867 x
FCF Yield -0% -0% -0% -0%
Price to Book 5.54 x 4.94 x 5.53 x 8.54 x
Nbr of stocks (in thousands) 29,968 29,992 29,997 32,081
Reference price 2 29.50 17.40 12.00 12.00
Announcement Date 18/05/21 30/05/22 21/04/23 18/04/24
1NOK in Million2NOK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 5.58 7.428 - 0.052 0.4545 0.004458
EBITDA 1 -7.499 -15.7 -33.95 -57.66 -39.3 -46.75
EBIT 1 -7.625 -15.98 -34.7 -59.11 -40.77 -48.38
Operating Margin -136.65% -215.13% - -1,13,674.66% -8,971.05% -10,85,224.09%
Earnings before Tax (EBT) 1 -7.586 -14.98 -33.09 -58.59 -40.57 -48.38
Net income 1 -7.586 -14.98 -33.09 -58.59 -40.1 -48.33
Net margin -135.96% -201.7% - -1,12,673.42% -8,823.56% -10,84,201.23%
EPS 2 -0.5042 -0.4999 -1.104 -1.954 -1.340 -1.510
Free Cash Flow - -8.871 -15.85 -34.63 -19.34 -29.35
FCF margin - -119.43% - -66,598.72% -4,254.27% -6,58,271.62%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 13/07/20 13/07/20 18/05/21 30/05/22 21/04/23 18/04/24
1NOK in Million2NOK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 59.2 45.4 160 102 67.7 45.2
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -8.87 -15.8 -34.6 -19.3 -29.3
ROE (net income / shareholders' equity) -23.2% -30.2% -32.8% -44.2% -46.9% -87.7%
ROA (Net income/ Total Assets) -11.4% -17.4% -19.5% -25.7% -25.5% -42%
Assets 1 66.27 86.25 169.6 228.3 157.5 115
Book Value Per Share 2 3.790 1.400 5.330 3.530 2.170 1.410
Cash Flow per Share 2 3.930 0.7900 4.650 2.760 2.310 1.450
Capex - 1.4 3.96 1.63 0.25 3.09
Capex / Sales - 18.84% - 3,127.86% 55.22% 69,375.93%
Announcement Date 13/07/20 13/07/20 18/05/21 30/05/22 21/04/23 18/04/24
1NOK in Million2NOK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EXACT THERAPEUTICS Stock EXACT Therapeutics
-48.75% 18.21M
MODERNA, INC. Stock Moderna, Inc.
+22.81% 46.81B
LONZA GROUP AG Stock Lonza Group AG
+47.13% 41.29B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.88% 41.37B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.87B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.33% 26.06B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.00% 19.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-1.43% 11.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.73% 12.39B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.48% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EXTX Stock
  4. Financials EXACT Therapeutics
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW